KPV Research Guide
Anti-inflammatory research peptide
KPV is the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH), studied for its anti-inflammatory effects in models of inflammatory bowel disease, skin inflammation, and oral mucositis. Despite its small size, it retains much of the anti-inflammatory activity of the parent alpha-MSH molecule.
Contents
|
3 amino acids Lysine-Proline-Valine |
Anti-inflammatory NF-kB pathway |
Gut + skin Primary research targets |
What is KPV?
KPV is the C-terminal tripeptide fragment (positions 11-13) of alpha-melanocyte-stimulating hormone, with the simple sequence Lysine-Proline-Valine. Despite being only three amino acids long, it has been shown in research to retain substantial anti-inflammatory activity of the much larger parent alpha-MSH molecule.
The research interest in KPV centers on its ability to deliver alpha-MSH-like anti-inflammatory effects in a smaller, more stable, and more easily synthesized form. This makes it a practical research compound for studies of inflammation pathways across multiple tissue types.
Aeternum Labs supplies KPV as a lyophilized powder verified to 99%+ purity by HPLC, with mass spectrometry sequence confirmation and full Certificate of Analysis published in the public COA library.
Mechanism of action
KPV exerts anti-inflammatory effects primarily through inhibition of the NF-kB signaling pathway, the master regulator of inflammatory gene expression. By blocking NF-kB activation, KPV reduces transcription of pro-inflammatory cytokines including TNF-alpha, IL-6, and IL-1-beta in cells and tissues exposed to inflammatory stimuli.
Research has shown KPV inhibits inflammation across multiple cell types including intestinal epithelial cells (relevant to inflammatory bowel disease research), keratinocytes (skin inflammation), and immune cells (general inflammatory response). The breadth of cellular targets reflects the broad anti-inflammatory utility of the alpha-MSH parent molecule.
Unlike the full alpha-MSH molecule, KPV does not significantly activate the melanocortin receptors that mediate alpha-MSH’s pigmentation effects. This selectivity makes KPV more useful for inflammation-focused research where pigmentation effects would be confounding.
Research history
KPV was characterized as the active anti-inflammatory fragment of alpha-MSH through structure-activity studies in the 1990s. The discovery that the simple tripeptide retained much of the parent molecule’s anti-inflammatory activity opened a more practical research pathway than working with the full alpha-MSH peptide.
Inflammatory bowel disease research using KPV emerged in the 2000s, with multiple studies demonstrating reduced colitis severity and improved intestinal barrier function in animal models. This work established KPV as a candidate for IBD research.
More recent research has expanded into oral mucositis (radiation- and chemotherapy-induced), atopic dermatitis, and other inflammatory conditions where the broad anti-inflammatory profile of KPV is potentially useful.
Half-life and pharmacokinetics
KPV has been administered in research via oral, topical, intraperitoneal, and subcutaneous routes. Oral bioavailability is unusually good for a small peptide, partly due to its small size and amino acid composition that resists complete proteolytic degradation.
Plasma half-life is short, but the anti-inflammatory effects on tissues persist for hours to days after administration due to the downstream gene expression effects of NF-kB pathway modulation.
Typical research doses
Oral research dose ranges in inflammatory bowel disease studies span approximately 100 microgram to 1 mg per kg body weight per administration, with daily dosing during active inflammation. Lower doses are commonly used for chronic anti-inflammatory research.
Topical research uses concentrations from 0.01% to 1% applied once or twice daily for skin inflammation models. Subcutaneous administration uses similar absolute dose ranges to oral protocols.
Compliance reminder
All dose ranges discussed are reported from peer-reviewed in vitro and animal research. They are not human-use dose recommendations.
Reconstitution protocol
Lyophilized peptides require reconstitution with a sterile solvent before any in vitro work. The standard solvent across virtually all research-peptide protocols is bacteriostatic water (sterile water with 0.9% benzyl alcohol), which prevents microbial growth across the typical four-week working window once a vial is opened.
Add the solvent slowly down the inside wall of the vial rather than directly onto the lyophilized cake. Swirl gently until the powder dissolves fully. Do not shake — agitation can denature peptide bonds and reduce assay potency. A clear, particle-free solution should result within thirty to sixty seconds.
Volume calculations are straightforward. For a 10 mg vial reconstituted with 2 mL of bacteriostatic water, each 0.1 mL of the resulting solution contains 0.5 mg of peptide. Researchers planning multi-week protocols should compute their volumes ahead of time and document the lot number against each preparation.
Storage and stability
Sealed lyophilized vials are stable at 0°F (−18°C) for up to twenty-four months in most research literature. Vials should be kept dry, light-protected, and away from temperature fluctuations. Avoid storing peptides in the freezer door, where each open-close cycle introduces thermal stress.
Once reconstituted, store the working solution at 36–46°F (2–8°C). Most lyophilized peptides remain stable in solution for twenty-eight days under refrigeration with bacteriostatic water as the diluent. For protocols longer than four weeks, reconstitute fresh batches as needed rather than extending a single working vial.
Repeated freeze-thaw cycles reduce peptide integrity. If long-term storage of a reconstituted sample is required, aliquot the solution into single-use volumes before freezing so each thaw uses a fresh aliquot.
Common stack pairings
KPV + BPC-157 (gut research)
BPC-157’s gut-protective and barrier-supporting effects pair with KPV’s anti-inflammatory NF-kB modulation. The combination addresses both barrier integrity and inflammation simultaneously in IBD-related research.
KPV + GHK-Cu (skin research)
GHK-Cu’s tissue remodeling and gene expression effects pair with KPV’s anti-inflammatory profile. The combination targets skin inflammation models with both repair and inflammation-modulating mechanisms.
How it compares
Compared to full alpha-MSH: KPV retains the anti-inflammatory activity but loses melanocortin receptor activity, making it more selective for inflammation research without confounding pigmentation effects.
Compared to BPC-157 in gut research: BPC-157 acts through VEGF and tissue protection mechanisms, while KPV acts through NF-kB inhibition. The two are mechanistically complementary in gut inflammation research stacks.
From the Aeternum library
KPV
- 99%+ purity verified by HPLC
- Mass spec sequence confirmation (KPV)
- LAL endotoxin screening
- Full Certificate of Analysis published
- Lyophilized powder
Frequently asked questions
What is KPV derived from?
KPV is the C-terminal tripeptide fragment (positions 11-13) of alpha-melanocyte-stimulating hormone (alpha-MSH), with the sequence Lysine-Proline-Valine. It retains much of the anti-inflammatory activity of the larger parent molecule.
How does KPV differ from full alpha-MSH?
KPV retains the anti-inflammatory activity but loses melanocortin receptor activity. This selectivity makes it useful for inflammation research without the confounding pigmentation effects that full alpha-MSH would produce.
What inflammatory conditions are studied with KPV?
Inflammatory bowel disease (IBD) research is the most-developed area, with multiple animal model studies demonstrating reduced colitis severity. Skin inflammation (atopic dermatitis), oral mucositis, and general inflammation research also use KPV as an experimental anti-inflammatory.
Can KPV be administered orally?
Yes. Oral bioavailability is unusually good for a small peptide, partly due to its small size and amino acid composition that resists complete proteolytic degradation. Oral administration is documented in published IBD research.
What dose ranges are used in research?
Oral research uses approximately 100 microgram to 1 mg per kg body weight per administration. Topical research uses 0.01-1% concentrations applied once or twice daily for skin inflammation models.
References
- Kannengiesser K, Maaser C, Heidemann J, et al. (2008). Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. View source
- Catania A, Lonati C, Sordi A, et al. (2010). The melanocortin system in control of inflammation. View source
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. View source
Reviewed by
The Aeternum Labs Research Team
Compounds, COAs, and protocol design
The Aeternum Labs research team verifies every batch in our library against published purity and identity standards. Articles in our research blog summarize publicly available scientific literature and are reviewed for accuracy by team members trained in peptide biochemistry and laboratory protocol design.
Related research
Category
Best peptides for tissue repair research →
Category
Best peptides for skin research →
Pair with
BPC-157 research guide →
Pair with
GHK-Cu research guide →
Research Disclaimer. All compounds discussed in this article are sold by Aeternum Labs for in vitro laboratory research purposes only. They are not intended for human or animal consumption, diagnosis, treatment, or prevention of any disease or condition. Information presented is summarized from publicly available scientific literature and should not be construed as medical advice.